Is US health care too broken to cure cancer?

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-16T04:35:49.193Z • Permanent link

Facts are beginning to emerge about the alarming state of US healthcare, and it's hard to ignore the stark reality: the country's healthcare system is failing to deliver on its promise to cure cancer. The story begins with the disappointing results from the National Cancer Institute's (NCI) annual report, which shows that despite significant investments in cancer research, the overall cancer death rate has increased in the United States. This trend is mirrored by the dismal performance of the National Institutes of Health (NIH), which has seen its funding slashed by over 20% in the past decade.

Data from the Centers for Disease Control and Prevention (CDC) paints a dire picture of the US healthcare landscape. According to the CDC, the country's cancer mortality rate has increased by 1.5% per year since 2010, with breast, lung, and colorectal cancers being the most deadly types of cancer. The root cause of this problem can be attributed to the US healthcare system's failure to adopt a comprehensive, evidence-based approach to cancer treatment. This is where Dr. Peter Piot, the former Director of the NCI, comes in. Dr. Piot has been vocal about the need for a more integrated approach to cancer research, one that combines cutting-edge technologies with traditional methods.

Recent data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program shows that the US is lagging behind other developed countries in terms of cancer mortality rates. The UK, for example, has seen a 20% reduction in cancer deaths since 2010, while the US has seen a mere 10% decline. This disparity is not just a matter of statistics; it has real-world implications for patients and families affected by cancer. The National Cancer Institute's own data shows that the US spends more on cancer research and treatment than any other country, but the results are not translating to better patient outcomes.

Rising cancer mortality rates in the US have significant implications for the Global Infrastructure domain, particularly for companies that rely on the healthcare industry for revenue and growth. Pharmaceutical giants like Pfizer and Johnson & Johnson are among the companies that have seen their stock prices plummet in recent years due to concerns about the effectiveness of their cancer treatments. The impact is not limited to the healthcare sector; cancer is a major driver of economic growth and innovation in many countries. In the US, the cancer industry is estimated to generate over $150 billion in revenue each year.

The consequences of the US healthcare system's failure to cure cancer are far-reaching and devastating. Cancer research communities are under immense pressure to deliver results, and the lack of progress is taking a toll on morale and funding. The National Cancer Institute's budget has been frozen for several years, and many researchers are being forced to seek funding from private sources. This is having a ripple effect throughout the research community, as funding is becoming increasingly competitive and unpredictable.

The US healthcare system's failure to cure cancer is not an isolated incident; it is part of a broader pattern of underinvestment in healthcare research and development. The Affordable Care Act (ACA), also known as Obamacare, was a major step forward in expanding access to healthcare, but it did not address the underlying issues with the US healthcare system. The ACA's focus on increasing access to healthcare rather than improving outcomes has led to a surge in demand for cancer treatments, which has in turn driven up costs and reduced quality.